LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Начало・Списък с акции・Kura Oncology Inc

Kura Oncology Inc

Затворен

СекторЗдравеопазване

8.81 1.85

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.58

Максимум

8.99

Ключови измерители
By Trading Economics
Приходи	7.7M -73M
Продажби	929K 18M
EPS	-0.828
Марж на печалбата	-401.495
Служители	260
EBITDA	7.4M -78M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+228.39% upside

Дивиденти
By Dow Jones
Следващи печалби	6.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-42M 802M
Предишно отваряне	6.96
Предишно затваряне	8.81

Настроения в новините

By Acuity

100%

320 / 344 Класиране в Healthcare

Kura Oncology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

8.06.2026 г., 22:20 ч. UTC

Придобивния, сливания и поглъщания

Salesforce to Buy m3ter in Nod Toward AI-Native Business Models

8.06.2026 г., 15:41 ч. UTC

Значими двигатели на пазара

American Battery Shares Jump on Energy Department Victory

8.06.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Rebound After Monday's Selloff -- Market Talk

8.06.2026 г., 23:37 ч. UTC

Пазарно говорене

Oil Edges Higher Amid Ongoing Supply Disruption Concerns -- Market Talk

8.06.2026 г., 23:25 ч. UTC

Пазарно говорене

Should Australia Consider State-Linked Commodities Export Desk? -- Market Talk

8.06.2026 г., 23:25 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.06.2026 г., 21:57 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Expects to Close Deal in 2Q of Fiscal 2027

8.06.2026 г., 21:56 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Agrees to Buy m3ter

8.06.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

8.06.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Settles Higher as Israel-Iran Exchanges Raise Tension -- Market Talk

8.06.2026 г., 19:01 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Pull Back on Weather Outlook -- Market Talk

8.06.2026 г., 18:52 ч. UTC

Пазарно говорене

Global Energy Roundup: Market Talk

8.06.2026 г., 18:52 ч. UTC

Пазарно говорене

CAD Needs Trade Deal to Trigger Sustained Rally -- Market Talk

8.06.2026 г., 18:17 ч. UTC

Пазарно говорене

Oil Pulls Back Further As Iran, Israel Put Strikes on Hold -- Market Talk

8.06.2026 г., 17:32 ч. UTC

Пазарно говорене

Bank of Canada Should Incorporate Unemployment Rate Into Its Forecast -- Market Talk

8.06.2026 г., 17:29 ч. UTC

Пазарно говорене

Crypto Market Still Stays in 'Extreme Fear' Amid Rebound -- Market Talk

8.06.2026 г., 17:29 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

8.06.2026 г., 16:55 ч. UTC

Придобивния, сливания и поглъщания

Monte dei Paschi: Mediobanca Integration Proceeding According to Plan

8.06.2026 г., 16:54 ч. UTC

Придобивния, сливания и поглъщания

Monte dei Paschi to Review Proposals From Banco BPM, Intesa Sanpaolo

8.06.2026 г., 16:40 ч. UTC

Пазарно говорене

Cryptocurrencies Rise After Iran and Israel Halt Exchanges of Fire -- Market Talk

8.06.2026 г., 16:31 ч. UTC

Пазарно говорене

No Recession in Canada, Scotiabank's CEO Says -- Market Talk

8.06.2026 г., 16:27 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in May -- Market Talk

8.06.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

8.06.2026 г., 16:03 ч. UTC

Придобивния, сливания и поглъщания

Orange Bought Stake From Lorca

8.06.2026 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Orange Completes Acquisition of Remaining 50% Stake in MasOrange

8.06.2026 г., 16:01 ч. UTC

Придобивния, сливания и поглъщания

Orange Acquires 100% Ownership of MasOrange

8.06.2026 г., 15:58 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

8.06.2026 г., 15:58 ч. UTC

Пазарно говорене

Gold Trims Losses After Israel, Iran Halt Exchanges of Fire -- Market Talk

8.06.2026 г., 15:55 ч. UTC

Пазарно говорене

Markets Price Small Chance USMCA Will Be Dismantled -- Market Talk

8.06.2026 г., 15:41 ч. UTC

Пазарно говорене

Gold Falls Below 200-Day Moving Average -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Kura Oncology Inc Прогноза

Ценова цел

By TipRanks

228.39% нагоре

12-месечна прогноза

Среден 28.11 USD 228.39%

Висок 40 USD

Нисък 15 USD

Според 10 анализатори от Wall Street, предложили 12-месечна ценова цел за Kura Oncology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

10 ratings

Купи

Задържане

Продай

Според 10 анализатори, дали борсови рейтинги на Kura Oncology Inc през последните 3 месеца.

Настроение

By Acuity

320 / 344 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.